Divestiture • Life Science

Ampersand Biomedicines Acquires AbCheck

On January 3, 2024, Ampersand Biomedicines acquired life science company AbCheck from Affimed Therapeutics AG

Acquisition Context
  • This is Ampersand Biomedicines’ 1st transaction in the Life Science sector.
  • This is Ampersand Biomedicines’ 1st transaction in Czech Republic.

Explore All 789 Divestiture Life Science Deals - Search the Database Free


M&A Deal Summary

Date January 3, 2024
Target AbCheck
Sector Life Science
Buyer(s) Ampersand Biomedicines
Sellers(s) Affimed Therapeutics AG
Deal Type Divestiture

Target Company

AbCheck

Plzen, Czech Republic
AbCheck discovers and optimizes human therapeutic antibodies with one of the industry’s most versatile technology platforms. AbCheck was founded in 2009 and is based in Plzen, Czech Republic.
Explore More Deals

Browse All 215,262 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

Ampersand Biomedicines

Boston, Massachusetts, United States

Category Company
Founded 2021
Sector Medical Products
DESCRIPTION

Ampersand Biomedicines is a multi-product platform company developing smarter medicine products. Ampersand Biomedicines was founded in 2021 and is based in Boston, Massachusetts.


Deal Context for Buyer #
Overall 1 of 1
Sector: Life Science 1 of 1
Type: Divestiture 1 of 1
Country: Czech Republic 1 of 1
Year: 2024 1 of 1

Seller Profile 1

SELLER

Affimed Therapeutics AG

Heidelberg, Germany

Category Company
Sector Life Science
DESCRIPTION

Affimed Therapeutics AG develops Human antibody therapeutics.


Deal Context for Seller #
Overall 1 of 1
Sector: Life Science 1 of 1
Type: Divestiture 1 of 1
Country: Czech Republic 1 of 1
Year: 2024 1 of 1